Core Viewpoint - Jiet Bio has evolved from a small workshop to a leading enterprise in the domestic biological laboratory consumables sector, focusing on core technology and long-term development to become a global leader in comprehensive solutions for biological laboratories [1][5]. Group 1: Company Development Stages - Jiet Bio was founded in 2001, with its main business encompassing the R&D, production, and sales of life science consumables related to cell culture and liquid handling [1][2]. - The company has undergone three key phases: the foundational phase (2001-2010), the expansion phase (2011-2019), and the capitalization and high-quality development phase (2020-present), overcoming numerous challenges to grow [1][2]. Group 2: Technological Innovation - Jiet Bio has invested 500 million yuan to establish an intelligent manufacturing factory, marking a significant step towards smart manufacturing and global market positioning [3]. - The factory, designed according to Industry 4.0 standards, enhances production efficiency by over 60% and maintains a product qualification rate of over 99.8% [3]. Group 3: Future Development Strategy - The company aims to transition from a "consumables leader" to a "comprehensive solutions provider for biological laboratories" during the 14th Five-Year Plan period, focusing on domestic and global markets [5]. - Jiet Bio plans to extend its supply chain upstream to core raw materials and downstream to laboratory instruments and reagents, creating a complete industry chain [5]. Group 4: Investor Returns - The company emphasizes investor returns, planning to maintain a cash dividend ratio of no less than 30% of net profit over the next three years [6]. - Jiet Bio aims for significant growth in the next 5-10 years, enhancing its core competitiveness and industry position while providing substantial long-term value to shareholders [6].

Core Viewpoint - Jiet Bio has evolved from a small workshop to a leading enterprise in the domestic biological laboratory consumables sector, focusing on core technology and long-term development to become a global leader in comprehensive solutions for biological laboratories [1][2]. Company Development - Founded in 2001, Jiet Bio specializes in the R&D, production, and sales of life science consumables related to cell culture and liquid handling [1]. - The company has undergone three key phases: foundational period (2001-2010), expansion period (2011-2019), and capitalization and high-quality development period (2020-present) [1]. - Jiet Bio aims to break the import monopoly and achieve domestic production of laboratory consumables, starting with core products like cell culture dishes and centrifuge tubes [1]. Capitalization and Growth - In 2020, Jiet Bio successfully listed on the Sci-Tech Innovation Board, becoming the first "domestic consumables stock," which accelerated its development through capital market leverage [2]. - The company has established a GMP-grade clean production base and transformed from a "single product supplier" to a "comprehensive solution provider" for biological laboratories, serving over 40 countries and regions [2]. Innovation and Technology - Jiet Bio has invested 500 million yuan in a smart manufacturing factory, marking a significant step towards intelligent manufacturing and global market positioning [2][3]. - The factory, designed according to Industry 4.0 standards, enhances production efficiency by over 60% and maintains a product qualification rate of over 99.8% [3]. Future Strategy - During the "14th Five-Year Plan" period, Jiet Bio's core strategy focuses on transitioning from a consumables leader to a comprehensive solution provider for biological laboratories, extending its supply chain upstream and downstream [4]. - The company plans to establish 2-3 regional headquarters or production bases overseas to enhance local production and service capabilities [4]. - Jiet Bio aims to maintain a research and development investment ratio of no less than 8% of revenue annually, with a focus on advanced technologies like 3D cell culture consumables and intelligent laboratory equipment [4]. Investor Returns - Jiet Bio is committed to returning value to investors through stable growth, reasonable dividends, and value enhancement, with a planned cash dividend ratio of no less than 30% of net profit over the next three years [5]. - The company has initiated a share buyback program, investing nearly 5 million yuan to repurchase 272,800 shares [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688026 证券简称：洁特生物 公告编号：2026-004 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 第四届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十七次会议于2026年1月19日 （星期一）以通讯的方式召开。会议通知已于2026年1月14日通过邮件的方式送达各位董事。本次会议 应出席董事7人，实际出席董事7人。 会议由董事长袁建华主持，部分高级管理人员列席了本次会议。会议召开符合有关法律、法规、规章和 《公司章程》的规定。经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于公司聘任董事会秘书的议案》 根据《公司章程》《董事会议事规则》的相关规定，经公司董事长提名，董事会提名委员会资格审查通 过，同意聘任鲍珉璋先生为公司董事会秘书，任期自本次董事会审议通过之日起至本届董事会任期届满 止。 具体内容详见公司披露于上海证券交易所 ...

Group 1 - The core point of the news is that Jiet Bio has seen a continuous increase in its stock price, rising 1.27% to 17.60 CNY per share, with a total market capitalization of 2.47 billion CNY and a cumulative increase of 5.39% over the past six days [1] - Jiet Bio specializes in the research, production, and sales of disposable plastic consumables for biological laboratories related to cell culture and liquid handling, with revenue composition being 60.24% from liquid handling, 30.74% from biological culture, and 4.98% from other sources [1] - The company is located in the Guangzhou Economic and Technological Development Zone and was established on April 11, 2001, with its listing date on January 22, 2020 [1] Group 2 - From the perspective of fund holdings, Huashang Fund has a significant position in Jiet Bio, with its fund holding 120,600 shares, representing 1.36% of the fund's net value, making it the sixth-largest holding [2] - The Huashang SSE STAR Market Comprehensive Index Enhanced A fund has a current scale of 87.04 million CNY and has achieved a year-to-date return of 7.58%, ranking 1517 out of 5520 in its category [2] - The fund managers, Ai Dingfei and Hai Yang, have notable performance records, with Ai having a best return of 144.96% during his tenure and Hai achieving a best return of 65.86% [2]

Core Insights - Jiet Bio's stock increased by 5.45% to 19.14 CNY per share, with a trading volume of 36.47 million CNY and a turnover rate of 1.40%, resulting in a total market capitalization of 2.687 billion CNY [1] Company Overview - Guangzhou Jiet Biofilter Co., Ltd. is located in the Yonghe Economic Zone of Guangzhou, Guangdong Province, established on April 11, 2001, and listed on January 22, 2020 [1] - The company's main business involves the research, development, production, and sales of disposable plastic consumables for biological laboratories related to cell culture and liquid handling [1] - Revenue composition: Liquid handling accounts for 60.24%, cell culture for 30.74%, other supplementary products for 4.98%, and instruments and other categories for 4.04% [1] Shareholder Information - Among the top ten circulating shareholders of Jiet Bio, one fund from Huaxia Fund, Huaxia CSI 500 Index Enhanced A (007994), has entered the list, holding 1.1212 million shares, which is 0.8% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 1.11 million CNY [2] - Huaxia CSI 500 Index Enhanced A was established on March 25, 2020, with a latest scale of 3.135 billion CNY, and has achieved a year-to-date return of 22.68% [2] Fund Manager Performance - The fund manager of Huaxia CSI 500 Index Enhanced A is Sun Meng, who has been in the position for 5 years and 220 days [3] - The total asset scale of the fund is 10.461 billion CNY, with the best return during the tenure being 126.46% and the worst return being 17.83% [3]

Core Logic - The company has over 20 years of experience in the biological laboratory consumables sector, focusing on biological culture and liquid handling, with leading technical strength and a comprehensive product matrix. The company is expected to maintain rapid growth and become a global leader in laboratory consumables [1] Group 1: Overseas Market - The company is leveraging an ODM model to penetrate the global biological laboratory consumables supply chain, establishing stable partnerships with international leaders like VWR and Thermo Fisher, and exporting products to over 70 countries. The company is enhancing its brand image as "reliable quality" and "outstanding cost performance" [2] - In 2024, the company's revenue from overseas self-owned brands is expected to increase by 46.07%, with overseas revenue accounting for 18.89% of total income. This indicates a successful transition from OEM to self-owned brand, capturing more value in the international laboratory consumables supply chain [2] Group 2: Domestic Market - The company is positioned to capitalize on the opportunity for import substitution in the current international trade environment, with a strong first-mover advantage in producing disposable plastic consumables for biological laboratories. The company plans to expand its sales network by establishing 12 offices in China in 2024, enhancing service responsiveness [3] - The company is also targeting industrial clients through high-quality cell factories, serving sectors like biopharmaceuticals and vaccine production. In 2024, sales from cell factory products are projected to grow by approximately 28.55%, indicating strong growth momentum [3] Group 3: Product Development and Cost Efficiency - The company is focused on developing high-end products such as liquid culture media and cell culture bags, while optimizing its product structure. It is also improving manufacturing processes and introducing automation to steadily reduce unit manufacturing costs [4] - The establishment of an intelligent manufacturing base will support the automation upgrade of production lines and the implementation of an intelligent warehousing system, which is expected to enhance order delivery efficiency and support global business demands [4] Group 4: Financial Projections - The company forecasts revenues of 652 million yuan, 772 million yuan, and 919 million yuan for 2025-2027, with year-on-year growth rates of 16.7%, 18.3%, and 19.1% respectively. The projected net profits for the same period are 98 million yuan, 118 million yuan, and 145 million yuan, with growth rates of 35.3%, 20.6%, and 23.2% respectively [4]

Investment Rating - The investment rating for the company is "Buy" [2] Core Views - The report highlights that the company has over 20 years of experience in the biological laboratory consumables sector, focusing on biological culture and liquid handling, with leading technical strength and a comprehensive product matrix. The company is expected to maintain rapid growth as its influence in overseas markets increases and both domestic industrial and research markets expand [3][4][5] Summary by Sections 1. Overseas Market - The company has entered the global biological laboratory consumables supply chain through an ODM model, establishing stable partnerships with international leaders like VWR and Thermo Fisher. The company has built a reputation for "reliable quality" and "outstanding cost performance," with overseas self-brand revenue increasing by 46.07% year-on-year in 2024, accounting for 18.89% of total revenue [4][14] 2. Domestic Market - The company is well-positioned to capitalize on the opportunity for import substitution in the current international trade climate. As one of the earliest producers of disposable plastic consumables in China, the company is expanding its sales network and has established 12 offices domestically in 2024. The sales of its cell factory products are expected to grow by approximately 28.55% year-on-year [5][49][53] 3. Product High-Endization and Smart Manufacturing - The company is focused on developing high-end products such as liquid culture media and cell culture bags while optimizing production processes to reduce manufacturing costs. The establishment of an intelligent manufacturing base is expected to enhance order delivery efficiency and support global business needs [6][15] 4. Financial Forecast and Investment Recommendation - The company is projected to achieve revenues of 652 million yuan, 772 million yuan, and 919 million yuan from 2025 to 2027, with year-on-year growth rates of 16.7%, 18.3%, and 19.1% respectively. The net profit attributable to the parent company is expected to be 98 million yuan, 118 million yuan, and 145 million yuan during the same period, with corresponding growth rates of 35.3%, 20.6%, and 23.2% [6][8][20]

Core Viewpoint - The credit rating agency has assigned a stable outlook to Guangzhou Jiete Biological Filtration Co., Ltd., reflecting its solid operational foundation and stable cooperation with global life science industry leaders, despite facing certain risks related to capacity digestion and reliance on overseas clients [3][6][16]. Company Overview - Guangzhou Jiete Biological Filtration Co., Ltd. specializes in the research, production, and sales of cell culture and related liquid handling life science consumables, maintaining a strong R&D capability in the field [3][5]. - The company has a credit rating of A+ with a stable outlook, indicating a good financial position and manageable debt levels [3][6]. Financial Performance - As of March 2025, the company's total assets reached 17.05 billion, with equity attributable to shareholders at 12.06 billion and total debt at 3.70 billion [3][4]. - The company's revenue for 2024 was 5.59 billion, with a net profit of 0.73 billion, showing a recovery in both revenue and profit scales [3][4]. - The cash-to-short-term debt ratio was notably high at 104.08, indicating strong liquidity [4][5]. Market Position - The company holds a significant position in the domestic supply chain for biological laboratory consumables, with stable cooperation with high-quality clients [6][9]. - The global life science industry giants continue to be major clients, ensuring a steady revenue stream [6][16]. Industry Environment - The life science industry in China has seen rapid growth in research funding, increasing from 59.7 billion in 2017 to 141.5 billion in 2023, with a compound annual growth rate of 15.5% [9][10]. - The market for biological laboratory consumables is projected to grow from 16.49 billion in 2022 to 23.42 billion in 2024, with a compound annual growth rate of 19.17% [10][11]. Risks and Challenges - The company faces uncertainties in capacity digestion and is highly dependent on overseas clients, with 66.13% of its revenue coming from international sales [5][16]. - The reliance on imported raw materials poses risks related to price fluctuations and geopolitical factors, which could adversely affect the company's performance [5][16]. Future Outlook - The credit rating agency maintains a stable outlook for the company, citing its strong cash position and low debt levels as positive indicators for future performance [6][9]. - The company is expected to continue benefiting from its established relationships with global life science leaders, although it must navigate the challenges posed by market competition and external economic factors [6][16].